The CEO of drug company AC Immune shared her thoughts on a recent failed tau vaccine trial, lessons learned, and what comes next. The…
Shedding further light on the mystery of Alzheimer’s pathology, a new study shows that individuals with a neurodegenerative language disorder called primary progressive aphasia…
While Biogen’s experimental Alzheimer’s treatment aducanumab faced yet another snag recently in its convoluted path toward FDA approval, other drugs companies are catching up:…
As part of our LiveTalk series, Being Patient spoke with Dr. Marwan Sabbagh, a neurologist and the director of the Cleveland Clinic Lou Ruvo…
While some scientists are focused on targeting beta-amyloid plaques to treat Alzheimer’s, others are honing in on another hallmark of the disease — pathological…
An Op-Ed by Benjamin Stecher Benjamin Stecher was diagnosed with Parkinson’s disease at the age of 29. He has since become actively involved in…
Alzheimer’s main hallmarks — beta-amyloid plaques and tau tangles — have long been the focus of the quest to come up with an Alzheimer’s…